Lumos To Highlight New LUM-201 Data And Analysis Presented At ENDO 2023 In Virtual KOL Webinar
Portfolio Pulse from Happy Mohamed
Lumos Pharma is hosting a virtual KOL Webinar to discuss new data and analysis on oral LUM-201 for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) from Phase 2 trials. The data shows a durable response after 12 months of LUM-201 administration and supports the physiologic mechanism of action of LUM-201.
June 21, 2023 | 1:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lumos Pharma's LUM-201 shows promising results in Phase 2 trials for iPGHD, with a durable response after 12 months and support for its mechanism of action.
The new data and analysis presented at the ENDO 2023 conference show that LUM-201 has a durable response after 12 months of administration, with clear evidence of potential drug effect observed in consistent improvement in average height velocity over baseline. This positive news is likely to have a short-term positive impact on Lumos Pharma's stock price, as it demonstrates the potential effectiveness of LUM-201 in treating iPGHD.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100